fulvestrant + dalpiciclib isethionate

A combination therapy consisting of fulvestrant, a selective estrogen receptor degrader (SERD), and dalpiciclib isethionate (SHR6390), an oral small molecule inhibitor of cyclin-dependent kinases 4 and 6 (CDK4/6). Developed by Jiangsu Hengrui Pharmaceuticals and its subsidiary Shandong Suncadia Medicine, this regimen is indicated for patients with hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-) locally advanced or metastatic breast cancer. Dalpiciclib functions by selectively inhibiting CDK4/6, thereby preventing the phosphorylation of the retinoblastoma (Rb) protein and blocking cell cycle progression from the G1 to the S phase. Fulvestrant competitively binds to estrogen receptors and induces their down-regulation and degradation. The combination has demonstrated clinical efficacy in the DAWNA-1 trial, significantly extending progression-free survival compared to fulvestrant alone in patients who progressed on prior endocrine therapy.

Brand names

FaslodexAiRuikang

Other names

dalpiciclib + fulvestrantSHR6390 + fulvestrant